Knight Therapeutics Doubles Down on Share Buyback Amid Record Growth

MONTREAL, QC – March 23, 2026 – Knight Therapeutics Inc. (TSX:GUD) is sending a powerful message of confidence to the market, announcing a significant expansion of its share buyback program just days after reporting a year of record-breaking financial results. The pan-American specialty pharmaceutical company received approval from the Toronto Stock Exchange to more than double its Normal Course Issuer Bid (NCIB), increasing the maximum number of common shares it can repurchase from 3,000,000 to 6,190,493.

This aggressive move, which authorizes the cancellation of shares representing approximately 10% of the company's public float, underscores a dual strategy of rewarding shareholders while actively pursuing an ambitious growth agenda. The announcement was well-received by investors, who pushed Knight’s stock to a new 52-week high of C$6.59 on Monday, signaling strong approval for management’s capital allocation strategy.

A Strategy of Shareholder Returns

Knight's decision to ramp up its share repurchase program is not a new tactic but an intensification of a long-standing practice. The company has consistently used NCIBs as a tool to return capital to shareholders, with similar programs active in 2022, 2023, and 2024. Under the current bid, which runs until August 21, 2026, Knight had already purchased 1,767,300 shares at a weighted average price of $6.08 between August 2025 and mid-March 2026.

The mechanics of a share buyback are straightforward: by reducing the number of shares outstanding, a company can mechanically boost key per-share metrics like earnings per share (EPS). This can make the stock appear more attractive on a valuation basis and is often interpreted by the market as a signal that management believes its shares are undervalued. For Knight, this signal is amplified by the sheer scale of the increase and its timing.

The buyback is supported by a formidable financial foundation. Knight concluded 2025 with record revenues of $452 million, a 24% increase over the prior year. Adjusted EBITDA also hit a record $73 million, while cash flow from operations surged to a record $69 million. This robust performance has allowed the company to significantly strengthen its balance sheet, shifting from a net debt position in the third quarter of 2025 to a net cash position of $27 million by year-end, holding $95.3 million in cash, cash equivalents, and marketable securities.

Balancing Buybacks with Ambitious Growth

While a large-scale buyback can sometimes raise questions about a company's growth prospects—suggesting a lack of high-return investment opportunities—Knight's recent activities paint a different picture. The company appears to be firing on all cylinders, using its strong cash generation to fund a multi-pronged strategy that combines shareholder returns with aggressive expansion.

In 2025 alone, Knight deployed over CAD 140 million to add more than 50 products to its portfolio through strategic acquisitions and partnerships. Major moves included the acquisition of the Paladin business and a deal with Sumitomo for a portfolio of Canadian assets, both of which were significant drivers of the year's revenue growth. The company also expanded its partnership with Incyte Biosciences to gain exclusive distribution rights for the cancer treatments Zynyz® and Niktimvo® across Latin America.

This acquisitive streak has continued into 2026. In March, Knight acquired a pharmaceutical development and manufacturing facility in Argentina, a move intended to vertically integrate some of its branded generic manufacturing. Simultaneously, it streamlined its portfolio by divesting the Canadian commercial rights for six non-core products for $21.5 million, demonstrating disciplined asset management.

Furthermore, the company is not neglecting organic growth. Sales, marketing, and R&D expenses climbed 30% in 2025, reflecting continued investment in its product pipeline and commercial infrastructure. Key regulatory submissions for Tavalisse® and MINJUVI® are underway in Latin American markets, representing potential future revenue streams. This flurry of activity suggests the buyback is less about a lack of options and more about a balanced and confident approach to capital allocation.

Analyst Confidence and Market Context

Financial analysts have largely endorsed Knight's strategy, viewing the increased buyback as a logical step for a company with strong cash flow and a clear growth trajectory. Following the release of its stellar 2025 results, several analysts reiterated positive outlooks. Research Capital analyst Andre Uddin raised his price target on the stock to $8.55 from $8.00, citing stronger-than-expected performance and improved visibility on growth from new product launches. RBC Capital followed suit, maintaining an "Outperform" rating and lifting its price target to C$8.50.

"This isn't just financial engineering; it's a reflection of solid operational performance and a clear strategy," one analyst covering the specialty pharma sector noted. "They are generating significant cash and are choosing to deploy it through a balanced approach of M&A, debt reduction, and shareholder returns. The buyback signals that management sees a disconnect between their operational success and the stock's valuation."

Despite the strong revenue performance, the company did report a net loss of $5.37 million for fiscal 2025, a swing from a $4.33 million profit in the prior year. However, this was primarily attributed to non-cash, mark-to-market revaluations of strategic fund investments rather than core operational weakness. Investors and analysts seem to have looked past this figure, focusing instead on the impressive growth in revenue, EBITDA, and operating cash flow.

Knight's strategy of pairing disciplined M&A with shareholder returns positions it as a mature yet growing player within the specialty pharmaceutical space. By focusing on the Canadian and Latin American markets, the company is carving out a significant niche, with its conservative balance sheet and lower stock volatility providing a measure of stability compared to some industry peers. The amended automatic share purchase plan (ASPP) will ensure the company can execute its buyback efficiently, even during self-imposed blackout periods, further cementing its commitment to this capital return strategy as it continues to build its pan-American pharmaceutical business.